Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

1998). These five subtypes have been grouped into two different classes based on pharmacology and biochemistry: the D1-like and the D2-like receptors. The D1-like receptors, D1 and D5, mediate ...

Figure 2: Saccharin and quinine preference are unaffected by the absence of functional D 2 dopamine receptors. Figure 4: Dopamine D 2-receptor-deficient mice show reduced sensitivity to ethanol ...

Using a novel deep learning approach, we evaluated the predictive power of the functional connectome during various states (resting state, movie-watching, and n-back) on episodic memory and working ...

Scientists have identified a food ingredient that could reverse some symptoms of autism. When administered, subjects were ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

The FDA has granted a priority review to dordaviprone for treating patients with recurrent H3K27M-mutant diffuse glioma, a ...

Equities research analysts at Wedbush boosted their FY2028 earnings per share estimates for shares of Chimerix in a research note issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now ...

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They ...

Shares of Chimerix (NASDAQ: NASDAQ: CMRX) climbed 12.5% as the company announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for dordaviprone, a potential ...

This is the first-ever drug approved for schizophrenia that does not target the D2 dopamine receptor in brain cells. Xanomeline works by targeting two specific receptors in brain cells ...

Investigational drug SPN-820, which activates the mTORC1 pathway, failed to significantly reduce depressive symptoms compared ...